Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Biomarkers for prognosis, early diagnosis and effectiveness of treatment.
研究概览
简要总结
Chagas disease is endemic to Latin America, and is of emerging importance in non-endemic countries because migration of people infected with T. cruzi. Current methods for diagnosis of T. cruzi infection are not ideal. Existing drugs for treatment are very limited, produce severe side-effects, and their effectiveness cannot be properly evaluated. Reliable biomarkers for prognosis, early diagnosis and effectiveness of treatment will be investigated.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients from endemic areas (Latin America)
- •Older than 18 years old and younger than 50
- •With serological confirmation of Chagas Disease infection with two different techniques
- •Indeterminate or initial cardiac form
- •No previously treated for Chagas Disease
排除标准
- •Co-morbidity: previous cardiac disease from other aetiology (ischemic, alcoholic or hypertensive), active inflammatory or immunology diseases for another agent. Hepatic disfunction
- •Pregnancy or lactation
研究组 & 干预措施
Chagas Disease
Participants diagnosed with Chagas Disease will be followed-up as a Case Group
干预措施: Benznidazole (Drug)
结局指标
主要结局
Biomarkers for prognosis, early diagnosis and effectiveness of treatment.
时间窗: 2 years
* Conventional polymerase chain reaction of T. cruzi in blood * Measurement of Brain natriuretic factor * Measurement of Prothrombotic factors * Measurement of antibodies against specific proteins of the trypomastigote of T. cruzi * Investigation of the phylogenetics of the parasite and the role of the lineages of T.cruzi in the clinical presentation and disease's progression
次要结局
- Cardiac function after antiparasitic treatment(2 years)